180 related articles for article (PubMed ID: 35453346)
1. BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer.
Lv Y; Lv X; Zhang J; Cao G; Xu C; Zhang B; Lin W
Antioxidants (Basel); 2022 Mar; 11(4):. PubMed ID: 35453346
[TBL] [Abstract][Full Text] [Related]
2. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.
Hussong M; Börno ST; Kerick M; Wunderlich A; Franz A; Sültmann H; Timmermann B; Lehrach H; Hirsch-Kauffmann M; Schweiger MR
Cell Death Dis; 2014 Apr; 5(4):e1195. PubMed ID: 24763052
[TBL] [Abstract][Full Text] [Related]
3. BRD4 contributes to high-glucose-induced podocyte injury by modulating Keap1/Nrf2/ARE signaling.
Zuo H; Wang S; Feng J; Liu X
Biochimie; 2019 Oct; 165():100-107. PubMed ID: 31325480
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-146b-5p protects oligodendrocyte precursor cells from oxygen/glucose deprivation-induced injury through regulating Keap1/Nrf2 signaling via targeting bromodomain-containing protein 4.
Li X; Zhang W; Xiao M; Wang F; Zhou P; Yang J; Chen X
Biochem Biophys Res Commun; 2019 Jun; 513(4):875-882. PubMed ID: 31003769
[TBL] [Abstract][Full Text] [Related]
5. Suppression of bromodomain-containing protein 4 protects trophoblast cells from oxidative stress injury by enhancing Nrf2 activation.
Wu Y; Mi Y; Zhang F; Cheng Y; Wu X
Hum Exp Toxicol; 2021 May; 40(5):742-753. PubMed ID: 33094643
[TBL] [Abstract][Full Text] [Related]
6. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
7. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
[TBL] [Abstract][Full Text] [Related]
8. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
9. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
10. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.
Zhang S; Duan S; Xie Z; Bao W; Xu B; Yang W; Zhou L
Front Pharmacol; 2022; 13():924817. PubMed ID: 35754474
[TBL] [Abstract][Full Text] [Related]
13. Glucose availability is a decisive factor for Nrf2-mediated gene expression.
Heiss EH; Schachner D; Zimmermann K; Dirsch VM
Redox Biol; 2013; 1(1):359-65. PubMed ID: 24024172
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
15. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
16. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
[TBL] [Abstract][Full Text] [Related]
17. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
18. Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition.
Ding H; Chen Z; Wu K; Huang SM; Wu WL; LeBoeuf SE; Pillai RG; Rabinowitz JD; Papagiannakopoulos T
Sci Adv; 2021 Nov; 7(47):eabk1023. PubMed ID: 34788087
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
20. Fuzzy complex formation between the intrinsically disordered prothymosin α and the Kelch domain of Keap1 involved in the oxidative stress response.
Khan H; Cino EA; Brickenden A; Fan J; Yang D; Choy WY
J Mol Biol; 2013 Mar; 425(6):1011-27. PubMed ID: 23318954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
